This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
Simponi (golimumab) in Ulcerative Colitis (UC): Sharing Real World Evidence and Experience – May 16th 2018

SIMPONI (Golimumab) is indicated for the treatment of moderately to severe active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy or who are intolerant to or have medical contraindications for such therapies.

Watch the chair Dr Mark Samaan and guest speaker Professor Carlos Taxonera give short summaries of their talks on SIMPONI’s Real World Evidence and Experience

UK Real World Evidence - Dr Mark Samaan

This video has been organised and fully funded by MSD

Dr Mark Samaan

Dr Mark Samaan is currently a Clinical Research Fellow at Guy's and St Thomas' NHS Trust, investigating therapeutic drug monitoring for biologic agents in IBD, as part of an MD program at Kings College.

Clinical outcomes of SIMPONI (Golimumab) as a first line anti TNF agent in adult patients with moderate to severe ulcerative colitis: Spanish evidence – Professor Carlos Taxonera

This video has been organised and fully funded by MSD

Professor Carlos Taxonera

With a medical degree in Spain in 1980, upon his PhD in 1988 at Complutense University of Madrid, Spain, Carlos Taxonera has served as Head of the IBD Unit, Gastroenterology Department, Hospital Clínico, Madrid, from 2003 to the present.

GB-GOL-00061 | Date of Preparation: January 2019